Search
N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine
go.drugbank.com/drugs/DB14196ApprovedSensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test. … N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen.
Synonyms: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine, N-Cyclohexyl-N'-phenyl-p-phenylendiamineIolopride I-123
go.drugbank.com/drugs/DB20028ExperimentalThe usage of the INN stem '-pride' in the name indicates that Iolopride I-123 is a sulpiride derivative and analogue. Iolopride I-123 has a monoisotopic molecular weight of 400.06 Da.
Categories: Compounds used in a research, industrial, or household settingICX-RHY
go.drugbank.com/drugs/DB05716ExperimentalThe drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. … ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.
Tirofiban
go.drugbank.com/drugs/DB00775ApprovedInvestigationalTirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glyc...
Synonyms: N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine19-norandrostenedione
go.drugbank.com/drugs/DB01434ExperimentalIllicitAfter 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.
SYN-101
go.drugbank.com/drugs/DB05958ExperimentalSYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.
PF-03187207
go.drugbank.com/drugs/DB05746InvestigationalBased on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.
Fasinumab
go.drugbank.com/drugs/DB12157Investigational[A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e
Adecatumumab
go.drugbank.com/drugs/DB05006InvestigationalEpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.